|
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
Vancouver, BC--(Marketwire) - Tekmira Pharmaceuticals Corporation (TSX:TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's lead RNAi therapeutic product candidate, is...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
CALGARY, July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel/carboplatin...
|
|
|
India needs to allow phase I trials of new drugs developed abroad: Dr Nadig
Indian regulatory authorities should allow to conduct phase 1 study for compounds developed abroad if its expertise and skill to invent new drugs is to be recognized internationally according to Dr Ramanand Nadig, president and deputy...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
CALGARY, July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel/carboplatin...
|
|
|
Oncolytics Biotech completes enrollment in head and neck cancer trial
(Datamonitor via COMTEX) -- ONCY | Quote | Chart | News | PowerRating -- Oncolytics Biotech, a Canadian biopharmaceutical company, has completed patient enrollment in the Phase II component of a Phase I/II UK trial of Reolysin...
|
|
|
Phase Forward and GSK sign multi-year software agreements
Phase Forward, a provider of data management software for clinical trials and drug safety, has signed multi-year, multi-million dollar contracts with GlaxoSmithKline (GSK) covering licencing and study support services.GSK and ...
|
|
|
Phase Forward signs new deal with GSK
Data management specialist Phase Forward has landed a multi-million dollar clinical trial services contract with GSK.Under yesterdays agreement, Phase Forward will provide GlaxoSmithKline (GSK) with licensing and study...
|
|
|
Phase Forward Customer GlaxoSmithKline Signs Multi-Year Agreements
- Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that GlaxoSmithKline (GSK) has signed multi-year, multi-million dollar contracts covering...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
CALGARY , July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.(TSX: ONC, NASDAQ: ONCY) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined...
|
|
|
Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
- Completion of Phase I Paves Way for Expanding Bavituximab Cancer Program - - Inclusion of Patients with Diverse Advanced Cancers Along with Promising Interim Phase II Data Suggest Bavituximab Could Have Broad Anti-Cancer...
|
|
|
Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
- Completion of Phase I Paves Way for Expanding Bavituximab Cancer Program - - Inclusion of Patients with Diverse Advanced Cancers Along with Promising Interim Phase II Data Suggest Bavituximab Could Have Broad Anti-Cancer...
|
|
|
Photocure submits application for marketing approval for Hexvix in USA to the FDA
--Photocure announces today that a New Drug Application (NDA) has been submitted to the US Health Authorities (FDA) to obtain approval for Hexvix for use in the detection of papillary bladder cancer using fluorescence cystoscopy.The NDA...
|
|
|
Photocure submits application for marketing approval for Hexvix, in USA to the FDA
Photocure announces today that a New Drug Application (NDA) has been submitted to the US Health Authorities (FDA) to obtain approval for Hexvix for use in the detection of papillary bladder cancer using fluorescence cystoscopy.The NDA...
|
|
|
GlaxoSmithKline signs contract for Phase Forward clinical trials software
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, has announced that GlaxoSmithKline (GSK) has signed multi-year, multi-million dollar contracts covering Licensing...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
A total of 30 patients have been treated in the Phase I/II trial (REO 011), including 23 head and neck cancer patients.Of these head and neck patients, 17 patients have been treated in the Phase II portion of the trial.
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
-(T-Net)--Tekmira Pharmaceuticals Corporation (TSX:TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's lead RNAi therapeutic product candidate, is being developed as a...
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
- Tekmira Pharmaceuticals Corporation (TSX:TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's lead RNAi therapeutic product candidate, is being developed as a...
|
|
|
Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Combination Reolysin and Paclitaxel/Carboplatin He
CALGARY, July 2 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc.(TSX: ONC, NASDAQ: ONCY) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K.trial of REOLYSIN combined with paclitaxel/carboplatin for patients with advanced cancers. The principal investigators...
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
VANCOUVER, BRITISH COLUMBIA, Jul 02 (MARKET WIRE) -- Tekmira Pharmaceuticals Corporation (TSX: TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's lead RNAi...
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
Tekmira Pharmaceuticals Corporation (TSX: TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's lead RNAi therapeutic product candidate, is being developed as a...
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 07/02/09 -- Tekmira Pharmaceuticals Corporation (TSX: TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's lead RNAi...
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
- Tekmira Pharmaceuticals Corporation (TSX:TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's lead RNAi therapeutic product candidate, is being developed as a...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R)
Oncolytics Biotech(R) Inc.Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial CALGARY, July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY)...
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
(Marketwire via COMTEX) -- TKMRF | Quote | Chart | News | PowerRating -- Tekmira Pharmaceuticals Corporation (TSX:TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's...
|
